Tag: Hepatitis C

22 Nov 2016

AbbVie pangenotypic combination shows promising results for Hepatitis C

AbbVie is running three large clinical research studies currently where a combination of glecaprevir and pibrentasvir has cured at least 98% of people with hepatitis C.

“The results we announced today bring us closer to providing a potential pan-genotypic, once-daily treatment option with 8 weeks of therapy for people living without cirrhosis and who are new to treatment,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “With our registrational program nearing completion, we’re on track to submit our next generation, pan-genotypic regimen to regulatory authorities by the end of this year in the U.S. and early 2017 in the European Union and Japan.”

For the full article please visit : https://news.abbvie.com/news/eight-weeks-treatment-with-abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-achieved-high-svr-rates-across-all-major-genotypes-chronic-hepatitis-c.htm#.WDR6wO5Nj68.link

[image source : http://www.investors.com/]